The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma

Hepatology

Volumn 57, Issue 6, 2013, Pages 2261-2273

  Sieghart, Wolfgang ^a   Hucke, Florian ^a   Pinter, Matthias ^a   Graziadei, Ivo ^b   Vogel, Wolfgang ^b   Müller, Christian ^a   Heinzl, Harald ^a   Trauner, Michael ^a   Peck Radosavljevic, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHLOROTRIANISENE; EPIRUBICIN; IODINATED POPPYSEED OIL;

ADULT; AGED; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CHEMOEMBOLIZATION; CHILD PUGH SCORE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; RETREATMENT; SCORING SYSTEM; TUMOR INVASION;

ADULT; AGED; AGED, 80 AND OVER; AUSTRIA; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; YOUNG ADULT;

EID: 84879106000     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26256     Document Type: Article

References (26)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
3. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30: 61-74.
4. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
5. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. HEPATOLOGY 2011; 53: 1020-1022.
6. Hucke F, Sieghart W, Schoniger-Hekele M, Peck-Radosavljevic M, Muller C. Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program? Wien Klin Wochenschr 2011; 123: 542-551.
7. Peck-Radosavljevic M, Sieghart W, Kolblinger C, Reiter M, Schindl M, Ulbrich G, et al. Austrian Joint OGGH-OGIR-OGHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma. Wien Klin Wochenschr 2011; 124: 104-110.
8. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37: 212-220.
9. Pinter M, Sieghart W, Hucke F, Graziadei I, Vogel W, Maieron A, et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2011; 34: 949-959.
10. Ebied OM, Federle MP, Carr BI, Pealer KM, Li W, Amesur N, et al. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer 2003; 97: 1042-1050.
11. Vogl TJ, Trapp M, Schroeder H, Mack M, Schuster A, Schmitt J, et al. Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center. Radiology 2000; 214: 349-357.
12. Memon K, Kulik L, Lewandowski RJ, Wang E, Ryu RK, Riaz A, et al. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: A subgroup analysis. J Hepatol 2012; 56: 1112-1120.
13. Sobin L, Wittekind C (eds.). UICC (2002) TNM classification of malignant tumours. 6th ed. New York: Wiley-Liss; 2002.
14. Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg 1964; 1: 1-85.
15. Sieghart W, Pinter M, Hucke F, Graziadei I, Schoniger-Hekele M, Muller C, et al. Single determination of C-reactive protein at the time of diagnosis predicts long term outcome of patients with hepatocellular carcinoma. Hepatology 2013; 57: 2224-2234.
16. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-181.
17. Pinter M, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, et al. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology 2012; 263: 590-599.
18. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Inter Rad 2010; 33: 41-52.
19. Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003; 9: 557-563.
20. Heinzl H, Kaider A. Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. Comput Methods Programs Biomed 1997; 54: 201-208.
21. Raoul JL, Bruix J, Greten TF, Sherman M, Mazzaferro V, Hilgard P, et al. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol 2012; 56: 1080-1088.
22. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
23. Bruix J, Raoul JL, Sherman M, Shan M, Lentini G, Nadel A, et al. Efficacy and safety of sorafenib in patients with hepatocellular carcinoma (HCC): subanalysis of SHARP trial based on Barcelona clinic liver cancer (BCLC) stage. J Hepatol 2009; 50( Suppl 1): 28-29.
24. Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Leberre MA, et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial. J Clin Oncol 2012; 30( Suppl 4, abstr LBA 154).
25. Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 2011; 55: 1309-1316.
26. Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 2012; 262: 708-718.